KR20200143400A - 아밀로이드증의 치료 및 예방 - Google Patents

아밀로이드증의 치료 및 예방 Download PDF

Info

Publication number
KR20200143400A
KR20200143400A KR1020207030523A KR20207030523A KR20200143400A KR 20200143400 A KR20200143400 A KR 20200143400A KR 1020207030523 A KR1020207030523 A KR 1020207030523A KR 20207030523 A KR20207030523 A KR 20207030523A KR 20200143400 A KR20200143400 A KR 20200143400A
Authority
KR
South Korea
Prior art keywords
antibody
seq
set forth
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207030523A
Other languages
English (en)
Korean (ko)
Inventor
타를로칸 니자르
삼세 필립 제이. 돌란
로빈 바버
Original Assignee
프로테나 바이오사이언시즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로테나 바이오사이언시즈 리미티드 filed Critical 프로테나 바이오사이언시즈 리미티드
Publication of KR20200143400A publication Critical patent/KR20200143400A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207030523A 2018-03-23 2019-03-22 아밀로이드증의 치료 및 예방 Ceased KR20200143400A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647341P 2018-03-23 2018-03-23
US62/647,341 2018-03-23
PCT/US2019/023528 WO2019183448A1 (en) 2018-03-23 2019-03-22 Treatment and prophylaxis of amyloidosis

Publications (1)

Publication Number Publication Date
KR20200143400A true KR20200143400A (ko) 2020-12-23

Family

ID=66041747

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207030523A Ceased KR20200143400A (ko) 2018-03-23 2019-03-22 아밀로이드증의 치료 및 예방

Country Status (13)

Country Link
US (1) US20210017278A1 (https=)
EP (1) EP3768311A1 (https=)
JP (1) JP7217287B2 (https=)
KR (1) KR20200143400A (https=)
CN (1) CN112040983A (https=)
AU (2) AU2019240413A1 (https=)
BR (1) BR112020019172A2 (https=)
CA (1) CA3095100A1 (https=)
EA (1) EA202092264A1 (https=)
MX (1) MX2020009920A (https=)
MY (1) MY203432A (https=)
SG (1) SG11202009295YA (https=)
WO (1) WO2019183448A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2237803T3 (en) * 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
SG10201604104PA (en) * 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
WO2018005967A1 (en) * 2016-06-30 2018-01-04 Prothena Therapeutics Limited Compositions for treating amyloidosis

Also Published As

Publication number Publication date
EP3768311A1 (en) 2021-01-27
MY203432A (en) 2024-06-27
CN112040983A (zh) 2020-12-04
CA3095100A1 (en) 2019-09-26
BR112020019172A2 (pt) 2021-01-26
AU2023202109A1 (en) 2023-05-18
EA202092264A1 (ru) 2020-12-03
JP7217287B2 (ja) 2023-02-02
WO2019183448A1 (en) 2019-09-26
AU2019240413A1 (en) 2020-10-08
MX2020009920A (es) 2020-12-10
US20210017278A1 (en) 2021-01-21
JP2021518393A (ja) 2021-08-02
SG11202009295YA (en) 2020-10-29

Similar Documents

Publication Publication Date Title
AU2022202649B2 (en) Antibody formulations and methods
US20230056881A1 (en) TARGETED TGFß INHIBITION
CN113631577B (zh) 抗滋养细胞表面抗原2(trop2)的抗体及包含其的抗体-药物偶联物
CN113150165B (zh) 双特异性四价抗体及其制造和使用方法
CN113906051B (zh) 对cd73具有特异性的结合分子及其用途
IL175523A (en) Interleukin-10 antibodies, preparations, methods for their preparation and uses
CN114984227A (zh) 抗tigit抗体在联合用药中的应用
CN116964101A (zh) 结合npr1激动剂的免疫球蛋白
KR20240101681A (ko) 신장 질환에 의한 빈혈을 치료하는 방법
KR20200143400A (ko) 아밀로이드증의 치료 및 예방
CN115141278A (zh) 抗vista抗体及其应用
HK40079898A (en) Use of anti-tigit antibodies in combination drug
AU2021264846A1 (en) TGFβR2 extracellular domain truncated molecule, fusion protein of TGFβR2 extracellular domain truncated molecule and anti-EGFR antibody, and anti-tumor use of fusion protein
HK40063743B (zh) 抗滋养细胞表面抗原2(trop2)的抗体及包含其的抗体-药物偶联物
HK40063743A (en) Anti-trophoblast cell surface antigen 2 (trop2) antibodies and antibody drug conjugates comprising same
HK40080391A (en) Use of anti-tigit antibody in the treatment of tumor or cancer
CN110785186A (zh) 用于治疗免疫性血小板减少的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601